Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 4/20 | 0.75 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.75 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.75 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.75 |
| ▸ | DPP4 | P27487 | 1/20 | 0.75 |
| ▸ | MEN1 | O00255 | 1/20 | 0.75 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.75 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.75 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.75 |
| ▸ | GAPDH | P04406 | 1/20 | 0.75 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.75 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.75 |
| ▸ | STAT6 | P42226 | 1/20 | 0.75 |
| ▸ | PI4KA | P42356 | 1/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.75 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.75 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.75 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.75 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Inosine SCHEMBL12763613 | 1.00 | SLC29A1 (0.75) | SLC29A1ADORA3MAPK1ADORA1SMN1; SMN2 | |
| Inosine SCHEMBL2229394 | 1.00 | SLC29A1 (0.75) | SLC29A1ADORA3MAPK1ADORA1SMN1; SMN2 | |
| Inosine SCHEMBL18653532 | 1.00 | SLC29A1 (0.75) | SLC29A1ADORA3MAPK1ADORA1SMN1; SMN2 | |
| Inosine SCHEMBL2046912 | 1.00 | SLC29A1 (0.75) | SLC29A1ADORA3MAPK1ADORA1SMN1; SMN2 | |
| Inosine SCHEMBL20138477 | 1.00 | SLC29A1 (0.75) | SLC29A1ADORA3MAPK1ADORA1SMN1; SMN2 | |
| Inosine SCHEMBL15804 | 1.00 | SLC29A1 (0.75) | SLC29A1ADORA3MAPK1ADORA1SMN1; SMN2 | |
| Inosine SCHEMBL4110068 | 1.00 | SLC29A1 (0.75) | SLC29A1ADORA3MAPK1ADORA1SMN1; SMN2 | |
| Inosine SCHEMBL6748954 | 1.00 | SLC29A1 (0.75) | SLC29A1ADORA3MAPK1ADORA1SMN1; SMN2 | |
| Inosine SCHEMBL298755 | 1.00 | SLC29A1 (0.75) | SLC29A1ADORA3MAPK1ADORA1SMN1; SMN2 | |
| Inosine SCHEMBL29436140 | 1.00 | SLC29A1 (0.75) | SLC29A1ADORA3MAPK1ADORA1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10869873-B2 | Methods and compositions for treating viral diseases | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-12-22 | — | — | US | disclosed |
| EP-2787999-B1 | METHODS AND COMPOSITIONS FOR TREATING VIRAL DISEASES | UNIV LELAND STANFORD JUNIOR (US) | 2019-01-23 | — | — | EP | disclosed |
| US-20180000926-A1 | METHODS OF INDUCING AN IMMUNE RESPONSE TO HEPATITIS C VIRUS | AGRAWAL, BABITA (CA) | 2018-01-04 | — | — | US | disclosed |
| US-20170000802-A1 | Methods and Compositions for Treating Viral Diseases | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2017-01-05 | — | — | US | disclosed |
| US-9364484-B2 | Methods and compositions for treating viral diseases | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2016-06-14 | — | — | US | disclosed |
| EP-3025727-A1 | METHODS OF TREATING LIVER DISEASE | The J. David Gladstone Institutes (US) | 2016-06-01 | — | — | EP | disclosed |
| US-9149463-B2 | Methods and compositions of treating a Flaviviridae family viral infection | THE BOARD OF TRUSTEES OF THE LELAND STANDFORD JUNIOR UNIVERSITY (US) | 2015-10-06 | — | — | US | disclosed |
| US-20150224170-A1 | Methods of Inhibiting Alphavirus Replication and Treating Alphavirus Infection | THE JOHNS HOPKINS UNIVERSITY | 2015-08-13 | — | — | US | disclosed |
| US-9101628-B2 | Methods and composition of treating a flaviviridae family viral infection | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2015-08-11 | — | — | US | disclosed |
| US-9061010-B2 | Methods of treating a Flaviviridae family viral infection and compositions for treating a Flaviviridae family viral infection | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2015-06-23 | — | — | US | disclosed |
| EP-1680137-A2 | MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULFONAMIDES AS INHIBITORS OF HCV REPLICATION | Intermune, Inc. (US) | 2006-07-19 | — | — | EP | disclosed |
| WO-2006020580-A2 | SYNTHETIC HYPERGLYCOSYLATED, PROTEASE-RESISTANT POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME | ALIOS BIOPHARMA INC. (US) | 2006-02-23 | — | — | WO | disclosed |
| WO-2006016930-A2 | METHODS FOR TREATING HCV INFECTION | INTERMUNE, INC. (US) | 2006-02-16 | — | — | WO | disclosed |
| US-20050267018-A1 | Macrocyclic compounds as inhibitors of viral replication | HOFFMANN-LA ROCHE INC. | 2005-12-01 | — | — | US | disclosed |
| WO-2005110455-A2 | COMBINATION THERAPY FOR TREATING HEPATITIS VIRUS INFECTION | INTERMUNE, INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| WO-2005067454-A2 | COMBINATION THERAPY FOR TREATING HEPATITIS C VIRUS INFECTION | VALEANT PHARMACEUTICALS NORTH AMERICA (US) | 2005-07-28 | — | — | WO | disclosed |
| WO-2005067963-A1 | USE OF POLYETHYLENE GLYCOL-MODIFIED INTERFERON-ALPHA IN THERAPEUTIC DOSING REGIMENS | INTERMUNE, INC. (US) | 2005-07-28 | — | — | WO | disclosed |
| WO-2005062949-A2 | METHOD FOR TREATING HEPATITIS VIRUS INFECTION | INTERMUNE, INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| WO-2005037214-A2 | MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULFONAMIDES AS INHIBITORS OF HCV REPLICATION | INTERMUNE, INC. (US) | 2005-04-28 | — | — | WO | disclosed |
| US-5559101-A | ANTITUMOR, ANTICARCINOGENIC, HIV | GENENCOR INTERNATIONAL, INC. (US) | 1996-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267018-A1 | Macrocyclic compounds as inhibitors of viral replication | EIF2AK2, HAVCR2, ZC3HAV1 | SLC29A1 1180/4885ADORA3 3911/4885MAPK1 2765/4885 |
| US-20180000926-A1 | METHODS OF INDUCING AN IMMUNE RESPONSE TO HEPATITIS C VIRUS | HAVCR2, CD74, IFNG | SLC29A1 4047/4885ADORA3 2745/4885MAPK1 4640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.